Sie suchten nach: fluorouracil (Maltesisch - Englisch)

fluorouracil*
fluorouracil*

5-fluorouracil
5-fluorouracil intravenous

leucovorin 5- fluorouracil
leucovorin

cisplatin u 5-fluorouracil
cisplatin and 5-fluorouracil

5-fluorouracil u leucovorin.
5-fluorouracil and leucovorin.

taxotere jintuża ma’ cisplatin u 5-fluorouracil.
taxotere is used with cisplatin and 5-fluorouracil.

meta jintuża flimkien ma’ cisplatin u 5-fluorouracil
in combination with cisplatin and 5-fluorouracil

docetaxel teva jintuża ma’ ċisplatinu u 5-fluorouracil.
docetaxel teva is used with cisplatin and 5-fluorouracil.

5-fluorouracil: injezzjoni bolus iv immedjatament wara leucovorin
5-fluorouracil: iv bolus injection immediately after leucovorin

docefrez jintuża ma’ cisplatin u ma’ 5-fluorouracil.
docefrez is used with cisplatin and 5-fluorouracil.

5-fluorouracil: injezzjoni bolus fil-vini immedjatament wara leucovorin
5-fluorouracil: intravenous bolus injection immediately after leucovorin

5-fluorouracil (f) 1000 mg/m2 kuljum għal 5 ijiem.
5-fluorouracil (f) 1000 mg/m2 per day for 5 days.

reazzjoni bħal din kienet irrapportata flimkien ma’ 5-fluorouracil topiku.
such a reaction has been reported with topical 5-fluorouracil.

onivyde, leucovorin u 5-fluorouracil għandhom jingħataw b’mod sekwenzjali.
onivyde, leucovorin and 5-fluorouracil should be administered sequentially.

ebda każ ma ġie rrapportat f’pazjenti li rċevew fluorouracil, doxorubicin u cyclophosphamide.
no cases were reported in patients who received fluorouracil, doxorubicin and cyclophosphamide.

wara li tkun ingħatajt onivyde se tingħata żewġ mediċini oħra, leucovorin u 5-fluorouracil.
after you have been given onivyde you will be given two other medicines, leucovorin and 5-fluorouracil.

tac = docetaxel, doxorubicin u cyclophosphamide fac = 5-fluorouracil, doxorubicin u cyclophospamide
tac = docetaxel, doxorubicin and cyclophosphamide fac = 5-fluorouracil, doxorubicin and cyclophospamide ci = confidence interval

5-fluorouracil, kull wieħed fl-ewwel u fit-tieni Ġurnata, kull ġimagħtejn
5-fluorouracil iv bolus/infusion, each on days 1 and 2, every 2 weeks

proporzjon ta’ riskju ta’ anqas minn 1 hu favur docetaxel + cisplatin + fluorouracil
a hazard ratio of less than 1 favors docetaxel + cisplatin + fluorouracil

sensitività eċċessiva għal capecitabine, jew għal kwalunkwe wieħed mill-eċċipjenti elenkati fis- sezzjoni 6.1, jew għal fluorouracil,
hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil,